Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2022 | The multidisciplinary nature of treating myocarditis

Han Zhu • 27 Oct 2022
SITC 2022
General Checkpoint Inhibitors

Han Zhu, MD, Stanford University, Standford, CA, discusses the multidisciplinary nature of treating myocarditis. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Han Zhu

2:00
Remaining challenges in reducing or preventing cardiotoxicity in patients receiving immunotherapy
Han Zhu • 27 Oct 2022
2:00
Risk factors for cardiotoxic events in patients treated with immune checkpoint inhibitors
Han Zhu • 27 Oct 2022
2:51
Predicting the development of myocarditis and investigating druggable targets
Han Zhu • 27 Oct 2022
4:04
Immune-mediated mechanisms in checkpoint inhibitor-induced myocarditis
Han Zhu • 27 Oct 2022

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals